Compare Centrus Energy Corp (LEU) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Centrus Energy Corp vs Pfizer Inc — how do they compare? Centrus Energy Corp trades at $143.23 (market cap $2.91B), while Pfizer Inc trades at $28.19 (market cap $158.56B). The key difference: Pfizer Inc is far larger — about 54.5× Centrus Energy Corp's market cap, and Pfizer Inc pays a 6.18% dividend while Centrus Energy Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Centrus Energy Corp for 29 Days and Pfizer Inc for 158 Days on average.
| LEU | PFE | |
|---|---|---|
Market Cap | $2.91B | $158.56B |
Volume | 903,777 | 44,138,282 |
Sector | Energy | Health |
52-Week High | $436.00 | $29.02 |
52-Week Low | $138.18 | $23.67 |
Typical Hold Time | 29 Days | 158 Days |
Enterprise Value | $2.22B | $210.06B |
Dividend Yield | — | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Centrus Energy (LEU) trades at $143.88, down 2.22% on the day, with a bearish technical outlook despite recent earnings beats. The stock shows elevated valuation metrics (P/E 75.18) but maintains profitability with 10.23% net margins. Recent news highlights Centrus' strategic position as the only US-licensed HALEU producer, benefiting from nuclear energy growth and Russian uranium import bans.
The investment case balances high growth potential in nuclear fuel supply against execution risks and premium valuation. Analyst consensus at $218.10 suggests 52% upside, but technical indicators and recent equity dilution from a $500 million offering present near-term headwinds. Success depends on contract execution and nuclear industry adoption timelines.
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Centrus Energy Corp
Centrus Energy is a leading supplier of nuclear fuel and services for the global power industry. It specializes in supplying low-enriched uranium and developing next-generation fuels for advanced nuclear reactors.
Read more on LEU →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
